Copyright Reports & Markets. All rights reserved.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Product
      • 1.4.2 Calcium Channel α2-delta Ligands
      • 1.4.3 Antidepressants
      • 1.4.4 Opioids
      • 1.4.5 Others
    • 1.5 Market by End User
      • 1.5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by End User
      • 1.5.2 Platinum Agents
      • 1.5.3 Taxanes
      • 1.5.4 Vinca Alkaloids
      • 1.5.5 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size
      • 2.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue 2014-2025
      • 2.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2014-2025
    • 2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Growth Rate by Regions
      • 2.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Regions
      • 2.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers
      • 3.1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers
      • 3.1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers
      • 3.2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Chemotherapy Induced Peripheral Neuropathy Treatment Price by Manufacturers
    • 3.4 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Chemotherapy Induced Peripheral Neuropathy Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product
    • 4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Product
    • 4.3 Chemotherapy Induced Peripheral Neuropathy Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
      • 6.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries
      • 6.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment by Product
    • 6.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment by End User

    7 Europe

    • 7.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
      • 7.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries
      • 7.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment by Product
    • 7.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
      • 8.1.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries
      • 8.1.2 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment by Product
    • 8.3 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
      • 9.1.1 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries
      • 9.1.2 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment by Product
    • 9.3 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
      • 10.1.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment by Product
    • 10.3 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment by End User

    11 Company Profiles

    • 11.1 Aptinyx
      • 11.1.1 Aptinyx Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Aptinyx Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Aptinyx Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
      • 11.1.5 Aptinyx Recent Development
    • 11.2 Asahi Kasei Pharma
      • 11.2.1 Asahi Kasei Pharma Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Asahi Kasei Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Asahi Kasei Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
      • 11.2.5 Asahi Kasei Pharma Recent Development
    • 11.3 Regenacy Pharmaceuticals
      • 11.3.1 Regenacy Pharmaceuticals Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
      • 11.3.5 Regenacy Pharmaceuticals Recent Development
    • 11.4 MAKScientific
      • 11.4.1 MAKScientific Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 MAKScientific Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 MAKScientific Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
      • 11.4.5 MAKScientific Recent Development
    • 11.5 Metys Pharmaceuticals
      • 11.5.1 Metys Pharmaceuticals Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Metys Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Metys Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
      • 11.5.5 Metys Pharmaceuticals Recent Development
    • 11.6 Nemus Bioscience
      • 11.6.1 Nemus Bioscience Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Nemus Bioscience Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Nemus Bioscience Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
      • 11.6.5 Nemus Bioscience Recent Development
    • 11.7 PledPharma
      • 11.7.1 PledPharma Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
      • 11.7.5 PledPharma Recent Development
    • 11.8 Sova Pharmaceuticals
      • 11.8.1 Sova Pharmaceuticals Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Sova Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Sova Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
      • 11.8.5 Sova Pharmaceuticals Recent Development
    • 11.9 DermaXon
      • 11.9.1 DermaXon Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 DermaXon Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 DermaXon Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
      • 11.9.5 DermaXon Recent Development
    • 11.10 Immune Pharmaceuticals
      • 11.10.1 Immune Pharmaceuticals Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Immune Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Immune Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
      • 11.10.5 Immune Pharmaceuticals Recent Development
    • 11.11 Kineta
    • 11.12 Krenitsky Pharmaceuticals
    • 11.13 PeriphaGen
    • 11.14 Apexian Pharma
    • 11.15 WinSanTor
    • 11.16 Solasia Pharma

    12 Future Forecast

    • 12.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Regions
      • 12.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Product
      • 12.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by End User
    • 12.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Forecast
    • 12.5 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Forecast
    • 12.6 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Forecast
    • 12.7 Central & South America Chemotherapy Induced Peripheral Neuropathy Treatment Forecast
    • 12.8 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Chemotherapy Induced Peripheral Neuropathy Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
      The classification of Chemotherapy Induced Peripheral Neuropathy Treatment includes Calcium channel α2-delta ligands, Antidepressants, Opioids and Other Drugs. And the proportion of Opioids in 2017 is about 27%, and the proportion is in decreasing trend from 2013 to 2017.
      Chemotherapy Induced Peripheral Neuropathy Treatment is widely used for CIPN cause by Platinum Agents, Taxanes, Vinca Alkaloids and Others. The most proportion of Chemotherapy Induced Peripheral Neuropathy Treatment is used in Platinum Agents, and the proportion in 2017 is 42%.
      North America is the largest sales place, with a sales market share nearly 41% in 2017. Following North America, Europe is the second largest sales place with the sales market share of 27%.
      The global Chemotherapy Induced Peripheral Neuropathy Treatment market is valued at 1300 million US$ in 2018 and will reach 2150 million US$ by the end of 2025, growing at a CAGR of 6.5% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Chemotherapy Induced Peripheral Neuropathy Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Chemotherapy Induced Peripheral Neuropathy Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Chemotherapy Induced Peripheral Neuropathy Treatment in these regions.
      This research report categorizes the global Chemotherapy Induced Peripheral Neuropathy Treatment market by top players/brands, region, type and end user. This report also studies the global Chemotherapy Induced Peripheral Neuropathy Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Aptinyx
      Asahi Kasei Pharma
      Regenacy Pharmaceuticals
      MAKScientific
      Metys Pharmaceuticals
      Nemus Bioscience
      PledPharma
      Sova Pharmaceuticals
      DermaXon
      Immune Pharmaceuticals
      Kineta
      Krenitsky Pharmaceuticals
      PeriphaGen
      Apexian Pharma
      WinSanTor
      Solasia Pharma

      Market size by Product
      Calcium Channel α2-delta Ligands
      Antidepressants
      Opioids
      Others
      Market size by End User
      Platinum Agents
      Taxanes
      Vinca Alkaloids
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Chemotherapy Induced Peripheral Neuropathy Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Chemotherapy Induced Peripheral Neuropathy Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Chemotherapy Induced Peripheral Neuropathy Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Chemotherapy Induced Peripheral Neuropathy Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Chemotherapy Induced Peripheral Neuropathy Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Chemotherapy Induced Peripheral Neuropathy Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now